Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

Merck (MRK) is a leading global healthcare company recognized for its groundbreaking pharmaceutical products and vaccines.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

4Q23 results included charges related to the Daiichi Sankyo collaboration .

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

(AP Photo/Rod Lamkey, Jr.) WASHINGTON (AP) — The man who hopes to be President Donald Trump’s health secretary repeatedly asked to see “data” or “science” showing vaccines are safe – but when an ...

In vaccines, Merck’s pneumococcal disease vaccine Capvaxive was recommended for approval to protect adults from invasive disease and pneumonia caused by streptococcus pneumoniae bacteria.